Constitutive Activation of MTORC1 Signaling Induced by Biallelic Loss-of-function Mutations in SZT2 Underlies a Discernible Neurodevelopmental Disease

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Aug 21

PMID 31430354

Citations 8

Authors

Yuji Nakamura

Kohji Kato

Naomi Tsuchida

Naomichi Matsumoto

Yoshiyuki Takahashi

Shinji Saitoh

Affiliations

Soon will be listed here.

Abstract

There have been increasing number of reports of SZT2-related neurological diseases, the main symptoms of which are epilepsy, developmental delay, macrocephaly and a dysmorphic corpus callosum. SZT2 functions as a regulator of mechanistic target of rapamycin complex 1 (mTORC1) signaling in cultured human cell lines and mouse tissues. However, it remains to be determined whether mutations in SZT2 in human patients alter mTORC1 signaling. In this study, we aimed to investigate the functional consequence of biallelic SZT2 variants in Epstein-Barr virus-induced lymphoblastoid cell lines (LCLs) established from two patients with a typical SZT2-related neurodevelopmental disease. Increased phosphorylation of S6 kinase and S6 was identified in patient-derived cell lines under amino acid-starved condition, suggestive of constitutive hyperactivation of mTORC1 signaling. This result was validated by constitutive lysosomal localization of mTOR in patients' LCLs. Furthermore, patients' LCLs display an excessive response to slight amino acid stimulation. Our data suggest the loss-of-function nature of SZT2 mutations in the patients, and consequent hyperactivation of mTORC1 signaling in response to both amino acid starvation and stimulation in their LCLs. By these functional analyses, the pathogenicity of newly identified SZT2 variants can be determined, allowing for more detailed characterization of genotype-phenotype correlations.

Citing Articles

Bi-allelic KICS2 mutations impair KICSTOR complex-mediated mTORC1 regulation, causing intellectual disability and epilepsy.

Buchert R, Burkhalter M, Huridou C, Sofan L, Roser T, Cremer K Am J Hum Genet. 2025; 112(2):374-393.

PMID: 39824192 PMC: 11866974. DOI: 10.1016/j.ajhg.2024.12.019.

Customized targeted massively parallel sequencing enables the identification of novel pathogenic variants in Tunisian patients with developmental and epileptic encephalopathy.

Ben Said M, Jallouli O, Ben Aissa A, Souissi A, Kamoun F, Fakhfakh F Epilepsia Open. 2023; 9(5):1697-1709.

PMID: 37867425 PMC: 11450609. DOI: 10.1002/epi4.12848.

Models of KPTN-related disorder implicate mTOR signalling in cognitive and overgrowth phenotypes.

Levitin M, Rawlins L, Sanchez-Andrade G, Arshad O, Collins S, Sawiak S Brain. 2023; 146(11):4766-4783.

PMID: 37437211 PMC: 10629792. DOI: 10.1093/brain/awad231.

The Dysfunctional Gangway: -associated Epilepsy with Thick Corpus Callosum.

Cherian A, Divya K, Pavuluri H, Thomas B J Pediatr Neurosci. 2022; 16(4):289-292.

PMID: 36531768 PMC: 9757505. DOI: 10.4103/jpn.JPN_128_20.

mTORC1 functional assay reveals SZT2 loss-of-function variants and a founder in-frame deletion.

Calhoun J, Aziz M, Happ H, Gunti J, Gleason C, Mohamed N Brain. 2022; 145(6):1939-1948.

PMID: 35773235 PMC: 9630660. DOI: 10.1093/brain/awab451.

References

Frankel W, Yang Y, Mahaffey C, Beyer B, OBrien T . Szt2, a novel gene for seizure threshold in mice. Genes Brain Behav. 2009; 8(5):568-76. PMC: 2728062. DOI: 10.1111/j.1601-183X.2009.00509.x. View

Sancak Y, Bar-Peled L, Zoncu R, Markhard A, Nada S, Sabatini D . Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell. 2010; 141(2):290-303. PMC: 3024592. DOI: 10.1016/j.cell.2010.02.024. View

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

Riviere J, Mirzaa G, ORoak B, Beddaoui M, Alcantara D, Conway R . De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet. 2012; 44(8):934-40. PMC: 3408813. DOI: 10.1038/ng.2331. View

Basel-Vanagaite L, Hershkovitz T, Heyman E, Raspall-Chaure M, Kakar N, Smirin-Yosef P . Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum. Am J Hum Genet. 2013; 93(3):524-9. PMC: 3769928. DOI: 10.1016/j.ajhg.2013.07.005. View

Falcone M, Yariz K, Ross D, Foster 2nd J, Menendez I, Tekin M . An amino acid deletion inSZT2 in a family with non-syndromic intellectual disability. PLoS One. 2013; 8(12):e82810. PMC: 3855772. DOI: 10.1371/journal.pone.0082810. View

Wolfson R, Chantranupong L, Saxton R, Shen K, Scaria S, Cantor J . Sestrin2 is a leucine sensor for the mTORC1 pathway. Science. 2015; 351(6268):43-8. PMC: 4698017. DOI: 10.1126/science.aab2674. View

Chantranupong L, Scaria S, Saxton R, Gygi M, Shen K, Wyant G . The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway. Cell. 2016; 165(1):153-164. PMC: 4808398. DOI: 10.1016/j.cell.2016.02.035. View

Vanderver A, Simons C, Helman G, Crawford J, Wolf N, Bernard G . Whole exome sequencing in patients with white matter abnormalities. Ann Neurol. 2016; 79(6):1031-1037. PMC: 5354169. DOI: 10.1002/ana.24650. View

10.

Venkatesan C, Angle B, Millichap J . Early-life epileptic encephalopathy secondary to SZT2 pathogenic recessive variants. Epileptic Disord. 2016; 18(2):195-200. DOI: 10.1684/epd.2016.0828. View

11.

Negishi Y, Miya F, Hattori A, Johmura Y, Nakagawa M, Ando N . A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly. BMC Med Genet. 2017; 18(1):4. PMC: 5237172. DOI: 10.1186/s12881-016-0363-6. View

12.

Wolfson R, Chantranupong L, Wyant G, Gu X, Orozco J, Shen K . KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1. Nature. 2017; 543(7645):438-442. PMC: 5360989. DOI: 10.1038/nature21423. View

13.

Peng M, Yin N, Li M . SZT2 dictates GATOR control of mTORC1 signalling. Nature. 2017; 543(7645):433-437. PMC: 5570594. DOI: 10.1038/nature21378. View

14.

Saxton R, Sabatini D . mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017; 168(6):960-976. PMC: 5394987. DOI: 10.1016/j.cell.2017.02.004. View

15.

Tsuchida N, Nakashima M, Miyauchi A, Yoshitomi S, Kimizu T, Ganesan V . Novel biallelic SZT2 mutations in 3 cases of early-onset epileptic encephalopathy. Clin Genet. 2017; 93(2):266-274. DOI: 10.1111/cge.13061. View

16.

Gordo G, Tenorio J, Arias P, Santos-Simarro F, Garcia-Minaur S, Moreno J . mTOR mutations in Smith-Kingsmore syndrome: Four additional patients and a review. Clin Genet. 2017; 93(4):762-775. DOI: 10.1111/cge.13135. View

17.

Nakamura Y, Togawa Y, Okuno Y, Muramatsu H, Nakabayashi K, Kuroki Y . Biallelic mutations in SZT2 cause a discernible clinical entity with epilepsy, developmental delay, macrocephaly and a dysmorphic corpus callosum. Brain Dev. 2017; 40(2):134-139. DOI: 10.1016/j.braindev.2017.08.003. View

18.

Pizzino A, Whitehead M, Sabet Rasekh P, Murphy J, Helman G, Bloom M . Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy. Am J Med Genet A. 2018; 176(6):1443-1448. PMC: 8025690. DOI: 10.1002/ajmg.a.38717. View

19.

Kato K, Mizuno S, Inaba M, Fukumura S, Kurahashi N, Maruyama K . Distinctive facies, macrocephaly, and developmental delay are signs of a PTEN mutation in childhood. Brain Dev. 2018; 40(8):678-684. DOI: 10.1016/j.braindev.2018.04.008. View

20.

Neitzel H . A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet. 1986; 73(4):320-6. DOI: 10.1007/BF00279094. View